BlackRock, Inc. Amends Schedule 13G/A for Ligand Pharmaceuticals Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G/A for Ligand Pharmaceuticals Inc., reporting ownership of 2,839,251 shares, representing 14.5% of the common stock. The filing indicates that BlackRock has sole voting power over 2,792,360 shares and sole dispositive power over all 2,839,251 shares. The filing also notes that the interest of iShares Core S&P Small-Cap ETF in Ligand Pharmaceuticals Inc. exceeds five percent of the total outstanding common stock. The amendment was signed by Spencer Fleming, Managing Director, on October 17, 2025.